Palo Alto Investors LLC Increases Holding in Clovis Oncology INC (CLVS)

Mindy Sparks
April 16, 2018

Clovis Oncology (NASDAQ:CLVS) has revealed a visible change in the trend volumes of the stock market recently. Its down 0.39, from 1.44 in 2017Q3. The ratio fall due to Clovis Oncology, Inc. positioning: 35 sold and 69 reduced. With 1.58M avg volume, 5 days are for Clovis Oncology Inc (NASDAQ:CLVS)'s short sellers to cover CLVS's short positions. 31 funds took positions and 78 increased positions. The stock has returned 9.22% during the last five consecutive trading sessions. About 1.63 million shares traded or 25.26% up from the average. (NASDAQ:CLVS). Metropolitan Life Ins stated it has 0.01% of its portfolio in Clovis Oncology, Inc. CLVS underperformed the S&P 500 by 32.98%.

Since October 16, 2017, it had 0 insider purchases, and 6 sales for $1.37 million activity. Orbimed Advisors LLC now owns 2,388,670 shares of the biopharmaceutical company's stock worth $196,826,000 after purchasing an additional 284,300 shares in the last quarter. The Camber Capital Management Llc holds 600,000 shares with $40.80 million value, up from 200,000 last quarter. (NASDAQ:CLVS). Kazazian Asset Mngmt Limited Liability Company, New York-based fund reported 19,517 shs.

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Md Sass Investors Services Inc who had been investing in Delta Air Lines Inc Del for a number of months, seems to be less bullish one the $37.27B market cap company. It now has negative earnings. The firm is also involved in the ARIEL3 and ARIEL4 confirmatory trials of rucaparib as a potential maintenance therapy and treatment for ovarian cancer; trial of rucaparib in prostate indications (TRITON) 2, a Phase 2 single-arm study in men with metastatic castrate-resistant prostate cancer; and TRITON3, a Phase 3 comparative study in men with mCRPC enrolling BRCA mutant and ATM, as well as engages in the various clinical studies for other indications. (NASDAQ:CLVS). Trust Department Mb Bancorporation N A has invested 0% in Clovis Oncology, Inc. SunTrust Banks dropped their target price on shares of Clovis Oncology from $95.00 to $85.00 and set a "buy" rating on the stock in a report on Tuesday, February 27th. During the same period in the prior year, the firm posted ($1.83) EPS. The company's revenue for the quarter was up 21746.2% on a year-over-year basis. research analysts anticipate that Clovis Oncology will post -4.78 earnings per share for the current year. Clovis Oncology had 14 analyst reports since October 23, 2017 according to SRatingsIntel. Out of 9 Wall Street analysts rating Clovis Oncology, 6 give it "Buy", 1 "Sell" rating, while 2 recommend "Hold". Clovis Oncology has a 1 year low of $45.42 and a 1 year high of $99.45. CLVS was included in 9 notes of analysts from August 24, 2016. Shares of CLVS moved upward with change of 6.95% to its 50-day Moving average. RBC Capital Markets upgraded the shares of CLVS in report on Thursday, February 22 to "Outperform" rating. On Monday, February 5 the firm earned "Buy" rating by Leerink Swann. 3,000 Clovis Oncology, Inc. Rating Scale: 1.0 represent "Strong Buy" and 2.0 signify "Buy" 3.0 while shows "Hold". Greenwood Capital Associates LLC grew its stake in Clovis Oncology by 21.6% during the fourth quarter. JPMorgan Chase restated a "buy" rating on shares of Clovis Oncology in a research report on Thursday, January 11th. On Tuesday, February 27 the rating was maintained by Stifel Nicolaus with "Buy". Oppenheimer reaffirmed a "hold" rating on shares of Clovis Oncology in a report on Wednesday, December 20th.


SCANA Corporation, through its subsidiaries, engages in the generation, transmission, distribution, and sale of electricity to retail and wholesale clients in SC. Schomburger Jeffrey K also sold $3.07 million worth of The Procter & Gamble Company (NYSE:PG) shares. It owns nuclear, coal, hydro, natural gas, biomass, and solar generating facilities.

Among 15 analysts covering Novo Nordisk (ADR) (NYSE:NVO), 7 have Buy rating, 0 Sell and 8 Hold. Therefore 23% are positive. The rating was downgraded by Wells Fargo on Friday, January 5 to "Market Perform". The company was upgraded on Wednesday, September 21 by Credit Suisse. The firm has "Overweight" rating given on Wednesday, May 17 by JP Morgan. The firm has "Buy" rating given on Thursday, December 14 by Raymond James. The firm earned "Overweight" rating on Tuesday, February 27 by Barclays Capital. The stock of Novo Nordisk A/S (NYSE:NVO) has "Strong Buy" rating given on Monday, October 19 by Jyske Bank. SunTrust maintained it with "Buy" rating and $30 target in Wednesday, August 24 report. Finally, Jennison Associates LLC bought a new stake in Clovis Oncology during the third quarter valued at approximately $15,167,000. Guggenheim maintained the shares of SCG in report on Tuesday, January 2 with "Hold" rating.

Investors sentiment decreased to 1.05 in 2017 Q4. Its down 0.39, from 1.44 in 2017Q3. It improved, as 15 investors sold HBHC shares while 70 reduced holdings. 61 funds opened positions while 120 raised stakes. Teacher Retirement System Of Texas owns 29,068 shares. Art Advisors Ltd Co accumulated 25,100 shares. Moreover, Emerald Mutual Fund Advisers has 0.54% invested in Clovis Oncology, Inc. Gamco Incorporated Et Al has 7,920 shares for 0% of their portfolio. Columbia Wanger Asset Management Ltd Company holds 514,996 shs. Tarbox Family Office Inc reported 100 shares. Roundview Capital Lc accumulated 4,430 shares or 0.06% of the stock. Kbc Group Nv holds 57,012 shares. (NASDAQ:CLVS). Stifel Financial holds 0% or 15,948 shares in its portfolio.

Other reports by Iphone Fresh

Discuss This Article

FOLLOW OUR NEWSPAPER